ClinicalTrials.gg
CompletedNCT05332106Updated Apr 18, 2022

Bioavailability of Estradiol Valerate and Dienogest 2 mg/2 mg With Regards to Reference Product

A Phase 1 interventional study of Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet and Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet in Bioequivalence, sponsored by Laboratorios Andromaco S.A.. Completed at 1 site in India. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Laboratorios Andromaco S.A. (part of Grünenthal GmbH) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

This study will investigate the bioavailability in fasting healthy, adult, human post-menopausal female subjects of 1 tablet formulation containing Estradiol Valerate and Dienogest 2 mg/ 2mg.

The study will be performed at a single site with 10 subjects. Participants will take 1 tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 7 days between each study period.

Read the detailed description

The primary objective of the study is to investigate the relative bioavailability of Estradiol Valerate and Dienogest 2mg/ 2mg of 1 tablet formulations with Estradiol Valerate and Dienogest 2mg/ 2mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

  • Test Product: Product manufactured by Laboratorios Andromaco S.A.
  • Reference Product: Climodien [Trademark], product Bayer plc. The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters area under the plasma concentration-time curve from time zero to time t (AUC0 0-t) and from time zero to infinite (AUC0 0-∞), and maximum plasma concentration (Cmax) for total Estradiol and Dienogest will be determined. Participants will be confined in the study site for approximately 42 hours during the entire study (for 10 hours pre-dosing and for 32 hours post dosing in both periods) during which pharmacokinetic (PK) blood samples will be obtained. 26 blood samples will be taken up to 72 hours after the administration in each period. The washout period between the two study periods will be at least 7 days. The samples from each participant will be analyzed with validated LC-MS/MS method for estimation of Estradiol and Dienogest in plasma. The safety objective is to evaluate the tolerability of both formulations in subjects by collecting adverse events.
02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Laboratorios Andromaco S.A. is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female literate volunteers of 40 to 65 years (both years inclusive) with of 18.50 - 29.99 Kg/m2 and weight > 50 Kg.
  2. Healthy volunteers as evaluated by medical history, vitals and general clinical examination.
  3. Normal or clinically insignificant biochemical, hematological, urine and serology parameters.
  4. Normal or clinically insignificant .
  5. Negative urine test for drugs of abuse and negative pregnancy test.
  6. Volunteers who are willing to use acceptable methods of (barrier method/IUD/surgical) or abstinence, for the entire duration of the study and do not plan to be pregnant for at least 1 month after the last drug administration.
  7. Volunteers who can give written and communicate effectively.

Exclusion criteria

Exclusion Criteria:

  1. History of any major surgical procedure in the past 03 months.
  2. History of any cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders.
  3. History of chronic alcoholism/ chronic smoking/ drug of abuse.
  4. Volunteers with known to Dienogest/Estradiol Valerate or any of the .
  5. History of consumption of tobacco containing products within 48 hours prior to proposed time of dosing.
  6. Volunteers who are positive for surface antigen, anti- antibody, treponemal antibodies and (HIV 1\&2) antibodies.
  7. Present or past history of intake of drugs or any prescription drug or over the counter (OTC) drugs within 14 days which potentially modify kinetics / dynamics of Dienogest/Estradiol Valerate or any other medication judged to be clinically significant by the investigator.
  8. History of consumption of grapefruit and/or its products within 10 days prior to the start of study.
  9. Volunteers who had participated in any other clinical study or who had bled during the last 03 months before check-in.
  10. History of consumption of one or more of the below, 48 hours prior to dosing: Xanthine containing food or drinks such as cola, chocolate, coffee or tea, citrus fruits or items (lime, lemon and orange), alcohol and any other food/beverage known to have interactions as deemed by the investigator.
  11. Volunteers who are dysphagic.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Estradiol Valerate and Dienogest Test Product.

    Participants will receive one tablet of the test formulation containing Estradiol Valerate and Dienogest 2 mg/ 2 mg.The tablet will be taken with water and in a fasting condition.

    Drug: Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet

  • Active comparator
    Estradiol Valerate and Dienogest Referent Product

    Participants will receive one tablet of the marketed reference containing Estradiol Valerate and Dienogest 2 mg/ 2 mg. The tablet will be taken with water and in a fasting condition.

    Drug: Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet

Interventions

  • DrugEstradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet

    Investigational Medicinal Product

  • DrugEstradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet

    Climodien (Bayer plc.)

06

What researchers measure

Primary outcomes

  1. Total Estradiol Valerate: area under the plasma concentration-time curve from 0 to time t (AUC0-72)

    26 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  2. Total Estradiol Valerate: Maximum plasma concentration (Cmax)

    26 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  3. Total Estradiol Valerate: Time to achieve maximum plasma concentration (tmax)

    26 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  4. Total Dienogest: area under the plasma concentration-time curve from 0 to time t (AUC0-72)

    26 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  5. Total Dienogest: Maximum plasma concentration (Cmax)

    26 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

  6. Total Dienogest: Time to achieve maximum plasma concentration (tmax)

    26 samples up to 72 hours will be taken after the administration in each period

    Time frame: From tablet intake and up to 72 hours after tablet intake

07

Study locations

1 site
  • Azidus Laboratories Ltd.
    Chennai, Tamil Nadu 600048, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Mar 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2022
First posted
Apr 18, 2022
StartActual
Mar 12, 2022
Primary completionActual
Mar 22, 2022
CompletionActual
Mar 22, 2022
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05332106
Responsible party
Sponsor
First posted
Apr 18, 2022
Start date
Mar 12, 2022
Primary completion
Mar 22, 2022
Completion
Mar 22, 2022
Last update
Apr 18, 2022

Study contacts

R. Amirtha, MD
principal investigator · Azidus Laboratories Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion